Figure 3.

Hazard ratio (95% CI) for association between eGFR variability and (A) death/dementia/persistent physical disability and (B) CVD events stratified by baseline CKD status with variability as a continuous variable (per 3 ml/min/1.73 m² difference) and according to tertiles (T) of standard deviation. Adjusted for age, sex, race/ethnicity, randomized arm (aspirin vs placebo), BMI, mean eGFR (BL-AV2), mean ACR (BL-AV2), diabetes, baseline frailty, smoking status, total cholesterol, LDL, mean SBP (BL-AV2), ACEi/ARB use, and diuretic use. Baseline CKD status determined by eGFR < 60 mL/min/1.73 m² or ACR ≥ 3 mg/mmol at year 2 visit and baseline or year 1 visit. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blocker; BL-AV2, baseline to annual visit 2; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; SBP, systolic blood pressure.